Nurix Therapeutics Inc
For the period ended Nov 30, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
NRIX$15.88-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| Year Ended November 30, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(143,948) | $(180,360) |
| Other comprehensive loss, net of tax: | ||
| Unrealized gain (loss) on available-for-sale marketable securities | 3,664 | (3,711) |
| Total comprehensive loss | $(140,284) | $(184,071) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.